Conferences - Results from #300

SESAUA 2023: A Contemporary Analysis of Treatment of Muscle Invasive Bladder Cancer Using the National Cancer Database: Factors Associated With Receipt of Non-aggressive Therapy March 16, 2023

SESAUA 2023: State-Of-The-Art Lecture: Advanced Imaging for Prostate Cancer: What’s Changed? March 16, 2023

SESAUA 2023: Patient-Reported Treatment Burden of Intravesical Therapy for Bladder Cancer March 16, 2023

SESAUA 2023: Review of Metastatic Disease Detection and Cost Analysis of Next Generation Imaging Use in Initial Staging of Prostate Cancer March 16, 2023

SESAUA 2023: Clinical Outcomes of Patients With mHSPC With PSA Decline to Undetectable Levels on Enzalutamide: Post Hoc Analysis of ARCHES Trail March 16, 2023

SESAUA 2023: Multi-Faceted Genomic, Pathologic, and Artificial Intelligence Analysis On Low Grade Noninvasive Bladder Tumors Reveals Signatures To Predict Downstream Tumor Recurrence March 16, 2023

SESAUA 2023: Mental Health Changes in Patients Undergoing Radical Cystectomy with Urinary Diversion March 16, 2023

SESAUA 2023: Long-Term Health Related Quality of Life in Prostate Cancer Patients Requiring Radiotherapy After Radical Prostatectomy March 16, 2023

SESAUA 2023: Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Demonstrates Poor Long-term Outcomes Following Immediate Radical Cystectomy: Opportunity For Neoadjuvant Pembrolizumab March 16, 2023

SESAUA 2023: State-Of-The-Art Lecture: Prostate Biopsy in 2023 – What Should I Know March 15, 2023

New Data Presented at EAU 2023 Highlight the Effects of Blue Light Cystoscopy in Bladder Cancer March 15, 2023

EAU 2023: Immunological Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer March 15, 2023

EAU 2023: Blue Light Cystoscopy Delays Time to Recurrence in Non-Muscle Invasive Bladder Cancer Patients Treated in a Real-World Setting March 15, 2023

EAU 2023: Is There a Role for Local Therapy to the Bladder in Patients with Oligometastatic Disease? March 13, 2023

EAU 2023: In Young Patients, Is Prostate-Sparing Radical Cystectomy a Safe Option for Muscle Invasive Bladder Cancer? What About Reproductive Organ-Sparing in Women? Debate March 13, 2023

EAU 2023: Clinical Staging for Bladder Cancer: Have Imaging Techniques Reached a Point Where We Can Avoid TURBT – at Initial Diagnosis? After Neoadjuvant Therapy? March 13, 2023

EAU 2023: Case-Based Debate: What Is the Optimal Treatment for Patients with High-Risk Muscle-Invasive Bladder Cancer Scheduled for Radical Cystectomy? Case Presentation – Use of Both Neoadjuvant and Adjuvant Systemic Therapy? One Is Enough March 13, 2023

EAU 2023: European Urology Oncology Lecture: The Future of Systemic Treatment in Patients with Locally Advanced and Metastatic Renal Cell Carcinoma March 13, 2023

EAU 2023: State-of-the-Art Lecture: PARP Inhibitors: For Which Mutations and When? March 13, 2023

EAU 2023: State-of-the-Art Lecture: Optimal Treatment Sequencing in the Area of Triplet Therapies for Hormone-Sensitive Disease March 13, 2023

Page 16 of 522